Immunogenicity of HspX/EsxS fusion protein of Mycobacterium tuberculosis along with ISCOMATRIX and PLUSCOM nano-adjuvants after subcutaneous administration in animal model

Avarvand, Arshid Yousefi; Meshkat, Zahra; Khademi, Farzad; Tafaghodi, Mohsen

doi:10.1016/j.micpath.2021.104842

Cited by 8 publications

(9 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, two nano-adjuvants ISCOMATRIX, a negatively charged particle, and PLUSCOM, a positively charged ISCOMATRIX, were also evaluated along with HspX/EsxS-fused protein via subcutaneous administration and the results were promising in animal model (unpublished data). However, as M. tuberculosisenters via respiratory tract, the mucosal administration of these formulations might rapidly induce the innate and adaptive immune response at the at the respiratory mucosal surfaces (10,19,20). Therefore, we followed two aims; 1) determine the potential of HspX/EsxS-fused protein in combination with ISCOMATRIX, PLUSCOM and MPLA after nasal administration and 2) comparison of the current results with our previous results.…”

Section: Introductionmentioning

confidence: 91%

“…The freeze-dried powders were combined with an aqueous phase containing saponin (8 mg in 4 mL of PBS (0.01 M), pH 7.4) (Sigma-Aldrich, USA) and then bath sonicated (Kerry, UK) at 37 °C for 10 minutes. Dynamic light scattering (DLS) (Zetasizer Nano, Malvern, UK) was used to measure the particle size and surface charge of nano-adjuvants (20)(21)(22)(23).…”

Section: Preparation Of Hspx/esxs Protein Iscomatrix and Pluscom Nano...mentioning

confidence: 99%

See 1 more Smart Citation

Enhancement of the immunogenicity of a Mycobacterium tuberculosis fusion protein using ISCOMATRIX and PLUSCOM nano-adjuvants after nasal administration in mice

Avarvand,

Meshkat,

Khademi

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: Tuberculosis (TB), a contagious disease caused by Mycobacterium tuberculosis (M. tuberculosis), remains a health problem worldwide and this infection has the highest mortality rate among bacterial infections. Current studies suggest that intranasal administration of new tuberculosis vaccines could enhance the immunogenicity of M. tuberculosis antigens. Hence, we aim to evaluate the protective efficacy and immunogenicity of HspX/EsxS fusion protein of M. tuberculosis along with ISCOMATRIX and PLUSCOM nano-adjuvants and MPLA through the intranasal administration in mice model. Methods: in present study, the recombinant fusion protein was expressed in Escherichia coli and purified and used to prepare different nanoparticle formulations in combination with ISCOMATRIX and PLUSCOM nano-adjuvants and MPLA. Mice were intranasally vaccinated with each formulation three times at an interval of 2 weeks. Three weeks after final vaccination, IFN-γ, IL-4. IL-17 and TGF-β concentration in supernatant of cultured splenocytes of vaccinated mice as well as serum titers of IgG1 and IgG2a and sIgA titers in nasal lavagewere determined. Results: According to obtained results, intranasally vaccinated mice with formulations containing ISCOMATRIX and PLUSCOM nano-adjuvants and MPLA could effectively induced IFN-γ and sIgA responses. Moreover, both HspX/EsxS/ISCOMATRIX/MPLA and HspX/EsxS/PLUSCOM/MPLA and their BCG booster formulation could strongly stimulate the immune system and enhance the immunogenicity of M. tuberculosis antigens. Conclusion: The results demonstrate the potential of HspX/EsxS-fused protein in combination with ISCOMATRIX, PLUSCOM and MPLA after nasal administration in enhancing immune response against of M. tuberculosis antigens. Both nanoparticles were good adjuvants in order to promote immunogenicity of TB fused antigen. so, nasal immunization with these formulations, could induce immune responses and considered as new TB vaccine or as BCG booster.

show abstract

Section: Introductionmentioning

confidence: 91%

Section: Preparation Of Hspx/esxs Protein Iscomatrix and Pluscom Nano...mentioning

confidence: 99%

Enhancement of the immunogenicity of a Mycobacterium tuberculosis fusion protein using ISCOMATRIX and PLUSCOM nano-adjuvants after nasal administration in mice

Avarvand,

Meshkat,

Khademi

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Inorganic nanoadjuvants have been used in vaccines for various diseases, such as coronavirus ( 95 ), cancer ( 91 , 96 ), and pertussis ( 97 ). Nanoadjuvants for TB vaccines are also being developed to enhance the immune response and extend the duration of protection ( 98 , 99 ).…”

Section: Adjuvantsmentioning

confidence: 99%

Advances in protein subunit vaccines against tuberculosis

Zhang,

Xu,

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Tuberculosis (TB), also known as the “White Plague”, is caused by Mycobacterium tuberculosis (Mtb). Before the COVID-19 epidemic, TB had the highest mortality rate of any single infectious disease. Vaccination is considered one of the most effective strategies for controlling TB. Despite the limitations of the Bacille Calmette-Guérin (BCG) vaccine in terms of protection against TB among adults, it is currently the only licensed TB vaccine. Recently, with the evolution of bioinformatics and structural biology techniques to screen and optimize protective antigens of Mtb, the tremendous potential of protein subunit vaccines is being exploited. Multistage subunit vaccines obtained by fusing immunodominant antigens from different stages of TB infection are being used both to prevent and to treat TB. Additionally, the development of novel adjuvants is compensating for weaknesses of immunogenicity, which is conducive to the flourishing of subunit vaccines. With advances in the development of animal models, preclinical vaccine protection assessments are becoming increasingly accurate. This review summarizes progress in the research of protein subunit TB vaccines during the past decades to facilitate the further optimization of protein subunit vaccines that may eradicate TB.

show abstract

“…In addition to recombinant live vaccines, HspX is often used successfully in subunit vaccines, either as a single antigen or in combination with others [ 67 , 68 , 69 , 70 , 71 ]. A study [ 70 ] has tested the immunogenicity of a DNA vaccine encoding HspX-PPE44-EsxV fusion antigens alone and in combination with BCG by prime-boost in mice.…”

Section: Strategies To Advance Bcgmentioning

confidence: 99%

Fighting Tuberculosis: In Search of a BCG Replacement

2022

View full text Add to dashboard Cite

Tuberculosis is one of the most threatening infectious diseases and represents an important and significant reason for mortality in high-burden regions. The only licensed vaccine, BCG, is hardly capable of establishing long-term tuberculosis protection and is highly variable in its effectiveness. Even after 100 years of BCG use and research, we still cannot unequivocally answer the question of which immune correlates of protection are crucial to prevent Mycobacterium tuberculosis (Mtb) infection or the progression of the disease. The development of a new vaccine against tuberculosis arises a nontrivial scientific challenge caused by several specific features of the intracellular lifestyle of Mtb and the ability of the pathogen to manipulate host immunity. The purpose of this review is to discuss promising strategies and the possibilities of creating a new vaccine that could replace BCG and provide greater protection. The considered approaches include supplementing mycobacterial strains with immunodominant antigens and genetic engineering aimed at altering the interaction between the bacterium and the host cell, such as the exit from the phagosome. Improved new vaccine strains based on BCG and Mtb undergoing clinical evaluation are also overviewed.

show abstract

Immunogenicity of HspX/EsxS fusion protein of Mycobacterium tuberculosis along with ISCOMATRIX and PLUSCOM nano-adjuvants after subcutaneous administration in animal model

Cited by 8 publications

References 42 publications

Enhancement of the immunogenicity of a Mycobacterium tuberculosis fusion protein using ISCOMATRIX and PLUSCOM nano-adjuvants after nasal administration in mice

Enhancement of the immunogenicity of a Mycobacterium tuberculosis fusion protein using ISCOMATRIX and PLUSCOM nano-adjuvants after nasal administration in mice

Advances in protein subunit vaccines against tuberculosis

Fighting Tuberculosis: In Search of a BCG Replacement

Contact Info

Product

Resources

About